Why the study?
MMVD significantly affects platelet function under high shear stress, but closure times measured with the PFA-200 across different stages of cardiac remodeling had not been investigated in dogs.
Does platelet function closure time differ between dogs with and without cardiac remodeling due to myxomatous mitral valve disease?
Does platelet function closure time differ between dogs with and without cardiac remodeling due to myxomatous mitral valve disease?
Assessing platelet closure times of C/ADP and C/EPI may provide valuable information for monitoring and staging myxomatous mitral valve disease in dogs.
Platelet function testing in canine MMVD requires clinical caution; leaves open need for prospective validation.
Chronic degenerative atrioventricular valve disease, particularly myxomatous mitral valve disease (MMVD), is the leading cause of heart failure in dogs.It significantly affects platelet function, especially under high shear stress, as well as potentially alters platelet activation and reactivity.Platelets are vital for coagulation and inflammation, and their function can be assessed using the Platelet Function , which simulates in vivo conditions.This study aimed to investigate the differences in closure time-measured using the PFA-200-in dogs with MMVD, with a focus on the impact of cardiac remodeling.The dogs were classified into the control, stage B1, stage B2, and stage C groups according to the American College of Veterinary Internal Medicine (ACVIM) guidelines.They were further categorized into the non-cardiac remodeling (normal, MMVD stage B1) and cardiac remodeling groups (MMVD stages B2 and C) based on cardiac remodeling status.Significant differences were found in the closure times of collagen-adenosine diphosphate (C/ADP) and collagen-epinephrine (C/EPI) between the non-cardiac and cardiac remodeling groups.Additionally, both closure times demonstrated a moderate positive correlation with the left atrial to aortic root ratio.Thus, assessing the closure times of C/ADP and C/EPI may provide valuable information for monitoring and staging MMVD in dogs.
No takes yet. Share an insight, caveat, or question.
An et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: